Biotech

The American Society of Hematology's 61st annual meeting is underway in Orlando, Florida. The four-day meeting kicked off Saturday and features a slew of presenters ranging from top pharma companies to tiny biotechs. The ASH, founded in 1958, is a professional organization...

Update from the annual meeting of the American Society of Hematology (ASH) suggested that initial data for Fate Therapeutics Inc’s (NASDAQ: FATE) FT500 and FT516 therapies were well received by both clinicians and investors, according to Wells Fargo. The Analyst Wells Fargo’s Jim...

Swiss biopharma Obseva SA (NASDAQ: OBSV), which is developing orally administered, clinical-stage compounds to treat women's reproductive health conditions, announced a positive late-stage clinical readout Monday for its investigational compound to treat heavy menstrual bleeding due to uterine...

Shares of thinly-traded micro-cap biotech Kalvista Pharmaceuticals Inc (NASDAQ: KALV) are seen moving to the downside Monday. What Happened Massachusetts-based KalVista, which focuses on developing small molecule protease inhibitors, said a Phase 2 study that evaluated its KVD001 in patients with...

Synthorx, Inc. (NASDAQ: THOR) shares are trading sharply higher after the company announced it would be acquired by Sanofi (NYSE: SNY) for $68 per share in cash, which represents an aggregate equity value of $2.5 billion. Sanofi expects to complete the acquisition in the first quarter of 2020. The...

Merck (NYSE: MRK) will acquire ArQule, Inc. (NASDAQ: ARQL) for $20 per share in cash for an approximate total equity value of $2.7 billion. ArQule is a biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases. See...

Investors have been piling into exchange traded funds again this year, mostly pure beta, core equity and fixed income funds. The list of the top asset-gathering ETFs reads like rundown of the usual suspects. There's nothing wrong with that, but as investors flock to broad market equity and...

Biotech stocks went back and forth but managed to end the week with a gain. As usual, some stocks swung wildly in reaction to catalysts, primarily clinical readouts. Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) more than doubled in a single session after its lead drug aced a pivotal trial in lupus...

Sage Therapeutics Inc (NASDAQ: SAGE) shares fell more than 60% Thursday following a negative readout for its lead asset in major depressive disorder. The Analysts Morgan Stanley analyst Matthew Harrison maintained an Overweight rating for Sage but lowered the price target from $217 to $125. (See...

Following Biogen Inc's (NASDAQ: BIIB) presentation of detailed top-line results for aducanumab at the Alzheimer's conference, the stock ended Thursday's session up about 3.5%. The presentation polarized analysts and clinicians alike, stirring a debate on whether the data is sufficient...

Biotech investment is fraught with risk. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts. These binary events, however, provide an opportunity for making huge profits for those investors placing the right bets. Even if the outcome is expected to be...

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 5) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)(presented positive Phase 3 data for pimavanserin in dementia-related psychosis) Allergan plc (NYSE:...

Biogen Inc's (NASDAQ: BIIB) presentation of aducanumab data at the Clinical Trials On Alzheimer's Disease Congress has drawn a mixed response. In late October, Biogen announced plans to revive its Alzheimer's program following a new analysis conducted by the company in consultation...

Shares of thinly-traded SAGE Therapeutics Inc NASDAQ: SAGE) are melting down after the company flunked in a late-stage trial of its lead CNS disorder drug candidate SAGE-217 in major depressive disorder, or MDD. What Happened To SAGE-217? Sage said its pivotal Phase 3 MOUNTAIN study evaluating...

Shares of small-cap biotech Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) are on a tear after the company reported positive clinical readout for its lead asset voclosporin in treating lupus nephritis, an autoimmune disorder. Aurinia has a single-product pipeline. Voclosporin is being evaluated for...